Rearrangement of the anaplastic lymphoma kinase (ALK) gene defines a distinct clinicopathologic subset of non‐small cell lung cancer (NSCLC) and occurs in approximately 3–7% of NSCLC cases, with a higher prevalence among younger, never/light smoker, and adenocarcinoma histology (Shaw et al, 2009). The gene discussed is ALK; the disease is lung cancer.